HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
Phase-appropriate and risk-based CMC development
to ensure fast to clinic, cost control, risk minimization,
and smooth transition to commercialization.
Expandable and flexible manufacturing capacity utilizing
single-use technologies, backed by an experienced team
and a robust Quality Management System, ensures on-time
delivery, efficient production, and consistent high quality.
With cutting-edge analytical instruments
and a highly skilled team, we provide reliable,
on-time testing services to support partners
across all stages of product development.
Strong expertise in media development and optimization
for fed-batch and perfusion processes, with a proven track
record of optimizing performance for various cell lines.
Candidate selection based on molecule thermo stability and manufacturability;
Early identification of potential critical quality attributes.
Establish high titer bulk pools from DNA in 2 weeks for CMC development;
Typical titer > 3 g/L at pool stage; > 5.9 g/L for single clones
Recombinant antibody / FC-fusion protein research grade material CHO cell based production;
Grams of antibody in 6 weeks from DNA to QC'd material.
Robust and high-quality Upstream process for mAb production;
Industry-standard Downstream process to reduce product and process related impurities.
In-house developed chemically defined media, robust cell line expression system and extensive technical expertise makes continuous bioprocessing applicable and affordable to any protein biologics.
Physical and chemical properties, purity, impurity, protein structure, affinity and other services,
covering almost full quality attributes in biopharmaceuticals
Integrated and systematic formulation and process development services focusing on monoclonal antibodies, fusion proteins, blood factors and bispecific antibodies.
We offer 50 ~ 2000L scale cell culture and drug substance (mAb, fusion protein) manufacturing with fed-batch or perfusion mode.
BOSCH isolated vial drug product filling line has completed > 60 batches @ 100% success rate.
Focusing on refining processes and enhancing product reliability, ultimately leading to a more efficient and effective route to market.
We have extensive experience in media development and optimization, including fed-batch basal media and feeds, as well as perfusion growth and production media.
Strong capabilities in ADC conjugation and formulation process development.
Strong capabilities in siRNA formulation & process development.
HJB, a subsidiary of Transcenta Holding Limited, is dedicated to providing high quality, speedy and flexible CDMO services for large molecules.
HJB boasts a team across all key functional areas. More than 50% hold advanced degrees (Ph.D. or M.S.) and have an average of 10 years of industry experience. Our senior management team consists of seasoned professionals with extensive CMC experience and a proven track record in leading teams at multinational corporations.
HJB boasts a team across all key functional areas. More than 50% hold advanced degrees (Ph.D. or M.S.) and have an average of 10 years of industry experience. Our senior management team consists of seasoned professionals with extensive CMC experience and a proven track record in leading teams at multinational corporations.
Quickly getting to clinical proof-of-concept is your primary goal. At HJB we believe innovators should not be burdened with excess amount of process development work early on. That’s why our team pre-optimized the entire platform for typical antibodies to help you reach the first-in-human milestone fast without compromising quality.
Quickly getting to clinical proof-of-concept is your primary goal. At HJB we believe innovators should not be burdened with excess amount of process development work early on. That’s why our team pre-optimized the entire platform for typical antibodies to help you reach the first-in-human milestone fast without compromising quality.
It is critical for company to secure low COGS supply, so drugs can be affordable to patients and their scientists can continue to innovate. HJB combines world-leading modular facilities, high productivity cell lines, internally developed media and efficient integrated continuous process to help you gain the edge on COGS control.
It is critical for company to secure low COGS supply, so drugs can be affordable to patients and their scientists can continue to innovate. HJB combines world-leading modular facilities, high productivity cell lines, internally developed media and efficient integrated continuous process to help you gain the edge on COGS control.
HJB' s GMP production facility in Hangzhou Biopharma Town is designed with a modular concept with independent intellectual property rights.
LEARN MORETo maximize facility output with significant lower cost of goods, improve process robustness and minimize operational risks, we are developing and implementing a continuous manufacturing platform called Highly Integrated Continuous Bioprocessing (HiCB).
LEARN MORE
HJB' s GMP production facility in Hangzhou Biopharma Town is designed with a modular concept with independent intellectual property rights.
LEARN MORE
To maximize facility output with significant lower cost of goods, improve process robustness and minimize operational risks, we are developing and implementing a continuous manufacturing platform called Highly Integrated Continuous Bioprocessing (HiCB).
LEARN MOREProjects Contracted
Clients Served
GMP DS/DP Batches Delivered
Cell Lines Developed
To learn more about HJB as well as its services and technologies, please send us a message by submitting the form, and we will get back to you as soon as we can. Looking forward to hearing from you and to discussing your specific project needs.
CDMO@hjbbio.com
